Kaveri Pohlman
Stock Analyst at Clear Street
(0.29)
# 4,206
Out of 4,876 analysts
22
Total ratings
19.05%
Success rate
-31.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Initiates: Buy | $32 | $22.91 | +39.68% | 1 | Jun 25, 2025 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.19 | - | 4 | Aug 1, 2024 | |
| GMAB Genmab | Maintains: Buy | $46 → $47 | $20.50 | +129.27% | 3 | Jun 27, 2024 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $20 → $30 | $7.76 | +286.60% | 2 | Apr 17, 2024 | |
| XNCR Xencor | Maintains: Buy | $56 → $38 | $8.14 | +366.83% | 1 | Apr 16, 2024 | |
| NUVB Nuvation Bio | Upgrades: Buy | $5 | $1.93 | +159.07% | 2 | Mar 26, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $62 | $23.15 | +167.82% | 1 | Mar 21, 2024 | |
| PYXS Pyxis Oncology | Initiates: Buy | $8 | $1.10 | +627.27% | 1 | Feb 9, 2024 | |
| EXEL Exelixis | Initiates: Buy | $27 | $43.67 | -38.17% | 1 | Dec 19, 2023 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $70 | $7.95 | +780.50% | 1 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.85 | +1,305.65% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $8 | $2.25 | +255.56% | 2 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12,320 → $4,928 | $1.12 | +439,900.00% | 2 | Feb 9, 2022 |
ArriVent BioPharma
Jun 25, 2025
Initiates: Buy
Price Target: $32
Current: $22.91
Upside: +39.68%
MacroGenics
Aug 1, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.19
Upside: -
Genmab
Jun 27, 2024
Maintains: Buy
Price Target: $46 → $47
Current: $20.50
Upside: +129.27%
Cullinan Therapeutics
Apr 17, 2024
Maintains: Buy
Price Target: $20 → $30
Current: $7.76
Upside: +286.60%
Xencor
Apr 16, 2024
Maintains: Buy
Price Target: $56 → $38
Current: $8.14
Upside: +366.83%
Nuvation Bio
Mar 26, 2024
Upgrades: Buy
Price Target: $5
Current: $1.93
Upside: +159.07%
Janux Therapeutics
Mar 21, 2024
Initiates: Buy
Price Target: $62
Current: $23.15
Upside: +167.82%
Pyxis Oncology
Feb 9, 2024
Initiates: Buy
Price Target: $8
Current: $1.10
Upside: +627.27%
Exelixis
Dec 19, 2023
Initiates: Buy
Price Target: $27
Current: $43.67
Upside: -38.17%
Arcus Biosciences
Aug 23, 2023
Reiterates: Buy
Price Target: $70
Current: $7.95
Upside: +780.50%
Aug 31, 2022
Initiates: Buy
Price Target: $12
Current: $0.85
Upside: +1,305.65%
Jul 7, 2022
Maintains: Buy
Price Target: $16 → $8
Current: $2.25
Upside: +255.56%
Feb 9, 2022
Maintains: Buy
Price Target: $12,320 → $4,928
Current: $1.12
Upside: +439,900.00%